Treatment of hepatitis C virus genotype 4 in the DAA era

Review Article

Treatment of hepatitis C virus genotype 4 in the DAA era 
Antonio Di Biagio Email author View ORCID ID profile , Lucia Taramasso and Giovanni Cenderello Virology Journal 201815:180
https://doi.org/10.1186/s12985-018-1094-4© The Author(s).

2018 Received: 22 November 2017 Accepted: 13 November 2018
Published: 22 November 2018

Abstract

The recently approved interferon-free DAA (direct antiviral agents) regimens have shown not only to be effective in terms of sustained virological response (SVR) rates (> 90%) but also well tolerated in most hepatitis C virus (HCV) infected patients. Nevertheless HCV genotypes are different and only a small percentage of trials consider genotype 4 (GT4), which was associated with lower rates of SVR compared with other genotypes before the arrival of the DAA’s. In this review, we discuss the efficacy of DAA therapy in GT4 HCV infection with specific reference to more recent studies, including those conducted in a ‘field-practice’ scenario. Overall, DAA-based regimens appear more effective also in the poorly-explored setting of patients with HCV GT4 infection. Despite an overall limited number of patients was evaluated, favorable results are being derived from studies on ombitasvir/paritaprevir/ritonavir, sofosbuvir and velpatasvir, whether or not in association with voxilaprevir, and with the new combined therapy glecaprevir + pibentasvir.

Read complete article online: https://virologyj.biomedcentral.com/articles/10.1186/s12985-018-1094-4